Yes, Neffy Is a Nasal Spray
Neffy (epinephrine nasal spray) delivers emergency treatment for anaphylaxis through a single-use nasal spray device. Users insert the nozzle into one nostril and press a plunger to release a 2 mg dose of epinephrine, which absorbs quickly through nasal membranes.[1]
How Does Neffy Work Compared to EpiPens?
Unlike auto-injectors like EpiPens that use intramuscular injections, Neffy avoids needles, making it easier for self-administration, especially in children or those with needle phobia. It provides similar epinephrine levels but requires no reconstitution or thigh exposure.[1][2]
Who Approves and Sells Neffy?
The FDA approved Neffy in August 2024 for adults and children weighing at least 30 kg, with a lower-dose version for kids 15-30 kg approved later. ARS Pharmaceuticals markets it in the U.S., pricing it around $710 per two-pack (similar to brand-name EpiPens).[1][3]
When Can You Expect Availability and Cost Details?
Neffy launched commercially in the U.S. in late 2024. A two-dose carton costs about $710 without insurance, though patient assistance programs offer it free or low-cost for eligible users. No generic versions exist yet due to recent approval.[3]
What Side Effects Do Users Report?
Common effects match epinephrine: nasal discomfort, throat irritation, headache, or increased heart rate. Rare risks include allergic reactions to excipients. Clinical trials showed no new safety signals versus injectables.[1][2]
How Does Neffy Compare to Auvi-Q or Generic Epinephrine?
| Product | Delivery | Dose Options | Approx. Cost (2-pack) | Needle-Free |
|---------|----------|--------------|-----------------------|-------------|
| Neffy | Nasal spray | 2 mg (≥30 kg), 1 mg (15-30 kg) | $710 | Yes |
| Auvi-Q | Auto-injector | 0.3 mg, 0.15 mg, 0.1 mg | $710 | Yes |
| EpiPen/Generic | Auto-injector | 0.3 mg, 0.15 mg | $100-$710 | No |[3]
Neffy stands out for portability (credit-card sized) but needs proper head positioning for absorption.
Are There Patent Concerns or Biosimilars?
Neffy holds method-of-use and formulation patents through at least 2037, per DrugPatentWatch.com.[4] No biosimilars challenge it yet, given its novelty as the first needle-free epinephrine option.
[1]: FDA Approval Summary: https://www.fda.gov/drugs
[2]: NEFI-1/2 Trial Data: https://www.nejm.org/doi/full/10.1056/NEJMoa2409109
[3]: ARS Pharmaceuticals Press Release: https://ir.arspharma.com/news-releases
[4]: DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/NEFFY